0001562180-20-000119.txt : 20200103 0001562180-20-000119.hdr.sgml : 20200103 20200103160142 ACCESSION NUMBER: 0001562180-20-000119 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200103 DATE AS OF CHANGE: 20200103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAVIS JOHN C. JR CENTRAL INDEX KEY: 0001741287 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38541 FILM NUMBER: 20505157 MAIL ADDRESS: STREET 1: C/O MAGENTA THERAPEUTICS STREET 2: 50 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Magenta Therapeutics, Inc. CENTRAL INDEX KEY: 0001690585 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-201-2700 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-01-02 false 0001690585 Magenta Therapeutics, Inc. MGTA 0001741287 DAVIS JOHN C. JR C/O MAGENTA THERAPEUTICS, INC. 100 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 false true false false Chief Medical Officer Common Stock 2020-01-02 4 M false 11294.00 9.49 A 19598.00 D Common Stock 2020-01-02 4 S false 11294.00 15.036 D 8304.00 D Stock Option (Right to Buy) 9.49 2020-01-02 4 M false 11294.00 0.00 D 2028-04-25 Common Stock 11294.00 224831.00 D This trade is pursuant to an active 10b5-1 plan. This transaction was executed in multiple trades at prices ranging from $15.00 to $15.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter. /s/ Zoran Zdraveski, Attorney-in-Fact for John C. Davis, Jr. 2020-01-03